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1. Introduction
  A number of diseases including many mood affective 
disorders like depression and anxiety and neurological 
disorders like schizophrenia have exhibited oxidative 
stress[1-5]. Free radical toxicity can be a contributory factor 
or a consequence of the disease itself. Such oxidative stress, 
brought about by reactive oxygen species (ROS), reactive 
nitrogen species and reactive sulphur species, leads to the 
injury of the cell/tissue and finally its death. The damaging 
effects of pro-oxidants vary considerably with the organisms 
studied, age, physiological state and diet[5]. Pro-oxidants 
are highly toxic to all types of biomolecules including DNA, 
proteins, lipids and carbohydrates. In our body such pro-
oxidants are scavenged by various antioxidants. Only when 
the pro-oxidants and antioxidants homeostasis is disturbed, 
there is oxidative stress.
  Premenstrual syndrome (PMS) which affects 30%-80% 
of the reproductive female age group has many features 
similar to that of depression and anxiety which however is 
limited to the late luteal phase of the menstrual cycle. The 
spectrum of this disorder ranges from mild (mere notice 
of symptoms) to a severe state of impairment of mood 
and behaviour (premenstrual dysphoric disorder, PMDD) 
upsetting the personal, professional and social life. The 
severe form PMDD, as categorized by DSM-IV, is seen in 
3%-8% of the total female population[6]. 
  The most common spectrum of symptoms observed 
in PMS are acne formation -70%, irritability -69%, 
depression -63%, swelling/bloating–63%. Further, 
PMS is just not one syndrome. It can be classified into 
different syndrome classes[7]. Most of the women fall 
under general discomfort syndrome and water retention 
syndrome. Depressive features fall under agitated-anxious 
or hostile type of atypical or non-endogenous depression[7]. 
Anxiety disorder features are present to a lesser extent 
than the depressive features[8,9]. There have been links 
between PMS and chronic schizophrenia as well as PMS 
and bulimia[10]. Past history of psychiatric illness and/or 
family history of depression[10-12], suicidal attempts[10,13] 
and a future risk of major depressive disorder have been 
correlated with PMS. However, the intensity of physical and 
emotional premenstrual complaints do not correlate[10]. It 
is also possible that premenstrual changes do not have the 
magnitude to qualify as a disorder as in some women they 
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are actually positive changes[10]. Many etiologies have been 
put forward from hormonal factors to nutritional disturbances 
to explain  the underlying pathology which however seems 
to be mutifactorial.  
  Since, PMS manifests various debilitating symptoms, in the 
present study we have tried to explore the role of oxidative 
stress in this condition. A preliminary study in PMS with a 
smaller sample size (n=6) had led us to infer that there is no 
indication of oxidative stress in such cases[14]. Therefore, in 
the present study we explored with a larger sample size and 
also with more sensitive markers of oxidative stress such 
as protein oxidation (protein thiols and carbonyls) and total 
antioxidant power of plasma.
  Proteins being the most abundant biomolecules in the 
plasma, cysteine and methionine amino acid residues of 
protein undergo dynamic and reversible oxidation in the 
earliest stage of oxidant attack protecting the oxidation at 
other sites forming disulfide linkage with other proteins or 
other low molecular weight thiols or glutathione resulting 
in the decreased concentration of the total reduced thiols. 
Estimating the reduced thiols indicates the antioxidant 
power of proteins, a drop in their levels being the earliest 
indication of oxidative stress[15-18]. The  persistence of the 
oxidants in the body manifests as irreversible oxidized 
protein products, amongst which the most prominent  are 
the protein carbonyls indicating the extent of the damage 
to proteins. On the other hand, the tests which measure the 
combined antioxidant effect of the nonenzymatic defenses 
in biological fluids may be useful in providing an index 
of the antioxidant system e.g. FRAP which measures the 
total antioxidant capacity of the plasma, serum and other 
biological fluids directly[19-21]. Sixty percent of FRAP is 
contributed by uric acid followed by ascorbic acid (15%), 
protein (10%), alpha-tocopherol (5%), bilirubin (5%) 
and others. There is no apparent interaction between 
antioxidants in the FRAP assay. FRAP however does not 
assay the sulfhydryl (SH) containing antioxidants [20].
  Thus, the ferric reducing antioxidant power of plasma 
(FRAP), plasma protein thiol (PPT) and plasma protein 
carbonyl (PPC) levels have been chosen as the study 
parameters in the present study.
2. Materials and methods
  Female volunteers of age 20-24 years from Manipal 
University were enrolled in this study. They had regular 
menstrual cycles with no other illness and were not on any 
medications. The study was conducted in department of 
Biochemistry, Kasturba Medical College, Manipal, from 
7th June 2005 to 6th July 2006. A total of 154 volunteers 
participated in this study. None of the subjects had any 
history of polycystic ovarian disease, smoking, alcohol 
consumption, drug abuse, insulin resistance and use of 
contraceptive pills. Nutritional difference was insignificant 
as they belonged to the same socioeconomic strata. The 
body mass index (BMI) for all the subjects was well within 
the normal range (22- 24 kg/m2). The subjects were divided 
into two major groups on the basis of COPE that is Calendar 
of Premenstrual Experiences[22].  The groups were: normal/
controls (who do not experience the premenstrual symptoms, 
COPE score=0) with median age=24 years, n=80; PMS 
(premenstrual syndrome; luteal score - follicular score曒 
30% of COPE score, follicular phase score<40) with  median 
age=23 years, n=74.
  Under aseptic conditions, 1.5 mL of venous blood was 
collected in EDTA vacutainers. The blood samples were 
collected from each volunteer at two time points namely, 
follicular phase sample (seven day period following 
menstruation) and luteal phase sample (seven day 
period before menstruation). The plasma was separated 
immediately after collection of sample by centrifuging 
at 4 000 rpm for two minutes. The separated plasma was 
transferred and stored in eppendorff tubes in the freezer 
at -20 曟. The parameters were assayed immediately or 
within next two days of collection. The plasma samples were 
allowed to thaw to room temperature before assay. 
  This study was carried out after clearance through the 
institutional ethical committee. The samples were obtained 
from the volunteers after their written consent.
  FRAP was measured according to the spectrophotometric 
method of Benzie et al[21]. PPT was estimated by treating the 
plasma with dithionitrobenzoic acid (DTNB)[15,16] and the 
absorbance was measured at 412 nm.  PPC was analyzed 
by treating the plasma with 2,4-dinitrophenylhydrazine 
(DNPH)[23] and the absorbance peak was measured at 
355 nm. The assay was based on the fact that several 
ROS can attack amino acids residues in proteins 
(particularly histidine, arginine, lysine, proline) to produce 
carbonyl functions that can react with DNPH to generate 
chromophobic dinitrophenylhydrazone which is  measured 
spectrophotometrically.
  Statistical analysis was carried out using the SPSS package 
(version 11.0).
3. Results
  There was no significant difference in the FRAP, PPT and 
PPC levels between the control subjects and the PMS group 
at both the time points, follicular as well as the luteal phases 
(Table 1). Further, an intra group comparison of the levels 
in the follicular and the luteal phases in the controls also 
showed no significant changes. However, a comparison of 
the PPT levels between the follicular and luteal phases of 
the PMS group indicated a significant decrease in PPT in the 
luteal phase (P< 0.05) (Table 1), the FRAP and PPC levels 
remaining unchanged.  
4. Discussion
 Under aerobic conditions, cells are always threatened with 
the insult from ROS which however is overcome by the highly 
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powerful antioxidant systems of the cell or body without any 
untoward effect, one such antioxidant being estrogen. In the 
present study therefore, the PMS group which is definitely 
associated with numerous stress symptoms[8,10,12,13] and 
vulnerable to the ROS attack  shows a significant change in 
PPT levels (P< 0.05) between the follicular phase and luteal 
phase when compared to their asymptomatic counterparts. 
However, FRAP and PPC levels remain unaffected when an 
intra- as well as inter-group comparison of the two phases 
between controls and PMS subjects was made. Earlier 
work carried out in our laboratory[14] and views expressed 
elsewhere[24-28] strongly support the observation that 
estrogens as well as progestins may exert  protective and 
adaptive response as potent antioxidants to the symptoms 
of PMS combating any oxidative stress. Further reports on 
plasma TBARS and erythrocyte antioxidant enzyme activities 
showed that in healthy eumennorrheic women, the levels 
were not altered in either of the two phases of the menstrual 
cycle except for the enzyme glutathione peroxidase[29,30]. A 
significant decrease in the PPT level in the luteal phase of 
the PMS group in this study, may be due to the overactivity 
of estrogen[31-34] in this phase which is responsible for the 
PMS symptoms on one hand and is also a potent antioxidant, 
on the other hand[24-30] thus, leading to an increase in 
the total turnover of PPT to combat any oxidative damage 
thereon, resulting in a marked decrease in its level in the 
plasma during this phase. Excessive activity of estrogens in 
the luteal phase of PMS group may stimulate its prooxidant 
nature also, which in turn significantly lowers the PPT 
levels, a sacrificial antioxidant[16]. Estrogens are converted 
to catecholestrogens which in turn produce oxygen radicals 
which bring about various types of damage[35].   However, 
the hormonal status of all the subjects in this study was well 
within normal limits in both the phases. 
  Moreover, other workers[36] have also suggested that 
neuroendocrine basis for the biobehavioral symptoms of 
PMS may involve oxytocin in conjunction with the female 
reproductive hormones and endogenous opioid peptides 
especially endorphins[6,37-39] promoting a better response 
to stress. Furthermore, estrogen influences the action of 
neurotransmitters like oxytocin and enkephalin probably 
affecting their antioxidant activity[10,40]. Hence, it can be 
hypothesized that hormones like estrogen, progesterone, 
oxytocin and neuropeptides could have attributed to the 
healthy antioxidant profile in PMS despite the transient 
decrease in the PPT levels in luteal phase of the PMS group.
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